Beta Drugs Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Growth intact despite headwinds: Revenue grew to INR396 cr, branded oncology up 20% and API up 23%, even as Platins non-supply flattened CDMO and tender delays pushed export revenue into FY27.
• Margin story has two layers: Gross margin improved to 55.52% and EBITDA margin to 22.57%, but net profit margin fell to 10.78% on extraordinary expenses; excluding those, it would have exceeded 12.5%.
• Diversification is accelerating, not defensive: The Nivian IVF acquisition, cosmetology tie-ups, and Derma breakeven are bets on adjacent growth, not a response to any oncology slowdown, which management says is running at 20% and rising globally.
• The Platins crisis is an industry-wide margin squeeze, not a Beta-specific demand problem: Carboplatin's NPPA price of INR2,850 leaves no hospital margin against INR2,300-2,400 cost, so the company simply stopped domestic supply and focused on higher-margin products elsewhere.
• What to watch next quarter: Whether the INR20-25 cr of delayed export tenders now awarded actually convert to revenue from May-June, the pace of Derma's 50% targeted growth, and any movement on the EU GMP audit now that three dossiers are filed.

Revenue Engine: What Grew, What Didn't, and Why

• Branded oncology carried the quarter: 20% growth came despite zero Platins supply in H2; the top 3-4 brands did the heavy lifting, with one brand crossing ~INR10 cr. Management sees 20-25% growth sustaining for 3-4 years on 20-25 new product launches including NDDS.
• API surged on a regulatory unlock: 23% growth followed the PIC/S audit clearance, which opens export doors that were previously closed. The API plant is now positioned to serve regulated markets.
• CDMO stalled on a single molecule family: Only 1% growth because Platins, the segment's anchor product group, were not supplied in H2. Without that disruption, CDMO would have grown 7%. Management guides 5-6% annual CDMO growth for the next 3-4 years.
• Exports fell on timing, not demand: The 11% decline reflects tenders that were awarded in March 2026 instead of December/January, pushing INR20-25 cr of revenue into FY27. Supply begins Q1, and management expects 50% export growth this year.
• Derma turned the corner on profitability: The segment became EBITDA positive, though gross margin compressed from 65% to 57-58% as the company invested in schemes to build scale. Revenue growth of 30-40% annually is the stated target for the next 3-4 years.
• Geopolitical risk is being managed through inventory: Certain products use petrol byproducts as raw material; the company bought and held 5 months of idle stock to avoid shortage. Price impact exists but is less severe for super-specialty products than generics, and management will pass through any material cost increase.

Rahul Batra: "Once you are doing certain business, the business become on auto mode where you as a person sitting there, if you are sincere thinking on a strategic point of view, so you don't have work to do... So it's about a bandwidth. When you have opportunities, why not utilize those bandwidth and become a better and more diversified company."

The Platins Problem: An Industry Crisis Beta Is Routing Around

• The math that broke the market: Carboplatin's NPPA-mandated price is INR2,850 per unit, while current industry costings run INR2,300-2,400. After retailer and wholesaler margins, hospitals earn nothing, so procurement has frozen across the board. Doctors and hospitals are, in management's words, "starving for Carboplatin."
• Beta's response was to stop, not stretch: The company did virtually no domestic Platins business last quarter, neither for CDMO nor its own brands. The only Platins supplied were export orders where no MRP price cap applies.
• The growth offset is already visible: Despite losing Platins, the company still delivered 10% sequential growth through new strategies and a shift toward other high-margin products. Management states flatly that Platins "will not make huge impact on growth" going forward.
• Export Platins may continue selectively: Where no MRP blockage exists, the company will still supply, but the domestic market is effectively written off until pricing economics change.

Rahul Batra: "Today doctors, hospitals, they are starving for Carboplatin. The chemotherapy starts from Carboplatin. But unfortunately, in India, the Carboplatin NPPA price is INR2850 and the costings which company are getting with Carboplatin is around INR2300, INR2400 as on today. So, there are no margins for hospitals."

Diversification Bets: Nivian, Cosmetology, and the Derma Build-Out

• Nivian acquisition adds a third growth vector: Beta acquired a 66.1% stake in the fertility/IVF company for INR69.4 cr at a INR105 cr valuation, with no promoter share dilution. The transaction closed in April 2026. Nivian is expected to grow at 30% for the next 3-4 years, with 4 new product launches planned this year and in-licensing of recombinants under exploration.
• The IVF market tailwind is structural: Management cites a 4.5% market share in an Indian IVF market projected to grow from INR2,000 cr to INR3,800 cr. If share is maintained, the IVF business more than doubles without gaining a point of share.
• Cosmetology is being built through exclusive European tie-ups: The company has tied up with Promoitalia and Fresyderm for fillers, mesotherapy, and premium anti-wrinkle products. Mesotherapy marketing approval was received in April, and more than 8 products are under registration.
• Derma is scaling with margin investment: The segment hit EBITDA breakeven this quarter, but gross margins compressed ~7-8 points to 57-58% as the company deployed schemes to drive adoption. The target is 50% growth this year, crossing INR50 cr in three years, with EBITDA margins reaching 12-14% at that scale.
• The intermediate plant is a strategic de-risking play: The INR27 cr KSM intermediate facility (land plus machinery) will bring precursor manufacturing in-house, eliminating dependence on Chinese suppliers for DMF documentation and QP audits. Commercialization is expected this year, and the company may also supply intermediates to other firms that have approached it. Margin uplift is modest at 1-1.5 bps, dependent on yield.

Rahul Batra: "We are just making everything in-house and we don't want to be dependent on anyone. So that is the main strategic decision which we have taken to come up with the intermediate plant."

Export Pathway: Tenders, Regulated Markets, and the INR200 cr Target

• The FY26 miss was a timing problem, now resolved: Tenders worth INR20-25 cr that were expected in December/January were awarded only in March 2026. Supply begins from May-June, so the revenue lands in FY27. Management expects no such delays this year.
• FY27 is positioned for a 50% export jump: From a base of INR71 cr, exports are guided to INR105-110 cr this year, with 50% of orders already in hand and more expected. H1 growth is pegged at ~30%, implying a back-half acceleration as new country registrations convert.
• The country footprint is expanding fast: Beta currently operates in ~31 countries and is opening around 14 more, taking the total to ~45. Over 200 dossiers have been submitted in the last 1.5 years, with ~100 new registrations expected this year.
• Regulated-market entry is the margin unlock: Current export EBITDA margins of 20-21% come from unregulated and semi-regulated markets. The company is transitioning 8 niche molecules (first or second generics) into regulated markets, which management expects will lift export margins to 23-25%.
• EU GMP is the next regulatory gate: The audit, earlier expected in April, was delayed because of a rule change: dossiers must now be filed before a line inspection can be scheduled. Three dossiers have been submitted, and the audit is now expected in September.
• Concentration risk exists but is managed: The majority of export business comes from five countries, representing 30% of the total. Management declined to name the countries, citing competitive confidentiality.

Financial Profile: Margins, Capex, and the Path to INR900 cr

• Gross margin improved on mix: The 280 bps expansion to 55.52% reflects a higher share of branded and API revenue, which carry better unit economics than CDMO and tender-driven exports.
• Net profit was depressed by one-time items: Net profit margin fell from 11.71% to 10.78%, but management states that excluding extraordinary expenses, it would have been above 12.5%. The nature of those expenses was not detailed.
• EBITDA margin guidance is 23-24%: As export and branded sales improve their revenue share, and as Derma scales past its investment phase, margins are expected to rise from the current 22.57%. Other income (INR11 cr, mostly FDR interest of INR8.5-9 cr plus duty drawback/MEIS) is included in this guidance.
• Capex is light relative to the growth ambition: Management committed to not more than INR25 cr in capex over the next 2 years. Existing oral capacity is at 40-45% utilization, injectable liquid has 35-40% idle capacity, and there is space to install two more Lyophilizers beyond the current unit running at 85%.
• The Vision 2030 math: Revenue is targeted to more than double to INR850-900 cr in 4 years, implying a 20-25% CAGR. The revenue mix shifts materially: branded formulation from 36% to 51%, exports from 18% to 30%, and CDMO from 39% to 13%, reflecting a deliberate move toward higher-margin, own-IP businesses.
• Debentures convert in May 2026: The conversion price is fixed at INR1,643 per share (face value INR10), with INR1,633 flowing into the securities premium account.

Rahul Batra: "With this particular setup, with this asset value, we see the revenue can scale up to INR700 crores to INR800 crores easily without doing any major investment."

Product Pipeline & Near-Term Launches

• Methotrexate launched in April: NPPA pricing was received in the first week of April, and the product is now in the market. Full-year revenue contribution is expected this year.
• Imatinib oral solution is 1-2 months out: The product is slated for launch in the next one to two months, adding to the branded oncology portfolio.
• NDDS pipeline has two near-term catalysts: One new NDDS will launch in the next 2 months. A second has received bioequivalence approval, with the CDSCO study starting soon, a report expected by November, and approval targeted for January-February.
• Derma fillers and mesotherapy are now live: Launched through an exclusive European tie-up, with mesotherapy marketing approval secured in April. These are premium-priced cosmetology products positioned for the clinic and med-spa channel.

Guidance & Commitments

Key Metrics